Notably, a 2015 paper analyzed data from the Food and Drug Administration's Adverse Event Reporting System (FAERS) and revealed a seven-fold risk increase for diabetic ketoacidosis in type 2 diabetic patients taking SGLT2 inhibitors [10-11]. Here, SLC5A2 is linked to diabetic ketoacidosis.